Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec

First Posted Date: 2013-06-19

Last Posted Date: 2017-02-10

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 458

Registration Number: NCT01880736

Locations: 🇯🇵
Novo Nordisk Investigational Site, Yokkaichi-shi, Mie, Japan

A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan

Completed

Conditions: Congenital Bleeding Disorder
Glanzmann's Disease

Interventions: Drug: eptacog alfa (activated)

First Posted Date: 2013-06-13

Last Posted Date: 2017-07-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 4

Registration Number: NCT01876745

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Other: No treatment given

First Posted Date: 2013-06-13

Last Posted Date: 2015-01-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 2092

Registration Number: NCT01877200

Bioequivalence Between Two Explorative Insulin Degludec Formulations and Between Two Explorative IDegAsp Formulations in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: insulin degludec
Drug: insulin degludec/insulin aspart

First Posted Date: 2013-06-04

Last Posted Date: 2015-10-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 58

Registration Number: NCT01868581

Comparison of Insulin Degludec With Insulin Glargine in Subjects With Type 1 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin degludec
Drug: insulin glargine

First Posted Date: 2013-06-04

Last Posted Date: 2015-09-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 63

Registration Number: NCT01868529

Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin degludec/insulin aspart 40
Drug: insulin degludec/insulin aspart 30
Drug: insulin degludec/insulin aspart 45
Drug: insulin degludec/insulin aspart 55
Drug: biphasic insulin aspart 30
Drug: insulin degludec
Drug: placebo
Drug: insulin aspart

First Posted Date: 2013-06-04

Last Posted Date: 2015-10-22

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 55

Registration Number: NCT01868568

A Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Insulin Detemir Titration Algorithms After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment With or Without Other Anti-diabetic Drugs (OADs)

Phase 4

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin detemir

First Posted Date: 2013-06-04

Last Posted Date: 2017-03-03

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 46

Registration Number: NCT01868542

Locations: 🇰🇷
Novo Nordisk Investigational Site, Daejeon, Korea, Republic of

Safety, Pharmacokinetics and Pharmacodynamics of Two IDegAsp (One Explorative) Preparations and Two Insulin Degludec (One Explorative) Preparations in Japanese Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: insulin degludec/insulin aspart 30
Drug: insulin degludec
Drug: insulin degludec/insulin aspart 45
Drug: placebo

First Posted Date: 2013-06-04

Last Posted Date: 2015-10-22

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 32

Registration Number: NCT01868555

Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy
Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: semaglutide
Drug: placebo

First Posted Date: 2013-05-31

Last Posted Date: 2014-04-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 170

Registration Number: NCT01866748

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Explorative Formulation of Insulin Degludec

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec
Drug: placebo
Drug: isophane human insulin

First Posted Date: 2013-05-30

Last Posted Date: 2015-10-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 64

Registration Number: NCT01865279

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy